Efficacy and safety of generic escitalopram versus Lexapro in the treatment of major depression: a multicenter double-blinded randomized controlled trial

Yimin Yu, Huafang Li, Biao Wang, Keqing Li, Xiufeng Xu, Jianguo Shi, Chengge Gao, Qingrong Tan, Yimin Yu, Huafang Li, Biao Wang, Keqing Li, Xiufeng Xu, Jianguo Shi, Chengge Gao, Qingrong Tan

Abstract

Background: Depression is an increasingly important public health problem in China, but only a small minority of patients with this condition receive treatment. One of the reasons for low treatment rates is the relatively high cost of imported antidepressant medications.

Aim: Compare the efficacy and safety of the generic form of the selective serotonin re-uptake inhibitory (SSRI) antidepressant escitalopram to the proprietary form of escitalopram (Lexapro) in the treatment of major depression.

Methods: A multicenter double-blinded randomized controlled trial enrolled 260 patients with depression and randomly assigned them to receive eight weeks of treatment with either generic escitalopram (n=130) or Lexapro (n=130). Efficacy was assessed by the Hamilton rating scale for depression (HAMD-17). Safety was assessed by evaluating adverse events reported by patients, regularly recording vital signs, and conducting laboratory tests and electrocardiograms.

Results: There were 35 (27%) dropouts during the 8 weeks of treatment in the generic escitalopram group and 32 (25%) in the Lexapro group. In the intention-to-treat analysis (i.e., including all patients) the mean (s.d.) drop in the HAMD total score at the end of the 8th week of treatment was 13.9 (8.2) in the generic escitalopram group and 14.3 (8.1) in the Lexapro group (t=0.44, p=0.664). The proportions of patients responsive to treatment (i.e., >50% drop in total HAMD score) were 69% and 67% in the generic escitalopram group and Lexapro group, respectively (χ (2)=0.16, df=1, p=0.690; and the proportions that achieved remission (i.e., final HAMD <7) were 51% and 49% (χ (2)=0.06, df=1, p=0.804). The most frequently reported adverse events were dry mouth (12.3%), nausea (9.2 %) and dizziness (6.2%) in the generic escitalopram group and nausea (10.8%), fainting (7.7%) and drowsiness (6.9%) in the Lexapro group. During the first 35 days of treatment, one suicide and two suicide attempts occurred in the generic escitalopram group and one suicide occurred in the Lexapro group (Fisher exact test, p=0.314).

Conclusion: Generic escitalopram is as effective and safe as Lexapro in the initial treatment of patients with moderate to severe episodes of major depression who seek treatment in the outpatient departments of psychiatric hospitals in China. Careful monitoring of the risk of suicidal events is an essential component of the treatment of depressed patients.

Trial registration: NCT00866593 (clinical.trails.gov).

Conflict of interest statement

Conflict of interest: The authors report no conflict of interest related to this manuscript.

Figures

Figure 1.. Flowchart of the study
Figure 1.. Flowchart of the study

References

    1. Murray CJL, Vos T, Lozano R, Naghavi M, Abraham D. Flaxman AD, et. al Global Burden of Disease Study Diseases and Injuries Group. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2223.
    1. Phillips MR, Zhang JX, Shi QC, Song ZQ, Ding ZJ, Pang ST, et al. Prevalence, associated disability and treatment of mental disorders in four provinces in China, 2001-2005: an epidemiological survey. Lancet. 2009;373:2041–2053.
    1. Feighner JP, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry. 1999;60(12):824–830.
    1. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescent. Am J Psychiatry. 2004;161(6):1079–1083.
    1. Kasckow JW, Welge J, Carroll BT, Thalassinos A, Mohamed S. Citalopram treatment of minor depression in elderly men: an open pilot study. Am J Geriatr Psychiatry. 2002;10(3):344–347.
    1. American Psychiatric Association . DSM IV Sourcebook. Virginia: Am Psychiatric Press Inc; 1994.
    1. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278–296.
    1. Guy W. ECDEU Assessment Manual for Psychopathology. Rockville, MD: U.S National Institute of Health, Psychopharmacology Research Branch; 1976. pp. 534–537.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Brit J Psychiatry. 1979;134(4):382–389.
    1. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.
    1. Zhang MY. Handbook of Rating Scales in Psychiatry. 2nd ed. Changsha: Hunan Science and Technology Press; 1998. (in Chinese)
    1. Ou JJ, Xun GL, Wu RR, Li LH, Fang MS, Zhang HG. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology (Berl) 2011;213(2-3):639–646.
    1. Schmitt L, Tonnoir B, Arbus C. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder. Neuropsychobiology. 2006;54(4):201–207.
    1. Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2005;66(11):1441–1446.
    1. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343–362.
    1. Chen HY, Li HF, Kuang WH, Zhao JP, Xie SP, Tao M. Randomized double-blind controlled trial of escitalopram versus citalopram in the treatment of depression. Shanghai Archives of Psychiatry. 2010;22(5):301–303. (in Chinese)
    1. Jick H, Kaye JA, Jick SS. Antidepressants and the Risk of Suicidal Behaviors. JAMA. 2004;292(3):338–43.
    1. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi